Sara Feola

1.1k total citations
33 papers, 685 citations indexed

About

Sara Feola is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sara Feola has authored 33 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 20 papers in Immunology and 17 papers in Molecular Biology. Recurrent topics in Sara Feola's work include Immunotherapy and Immune Responses (20 papers), CAR-T cell therapy research (17 papers) and Virus-based gene therapy research (14 papers). Sara Feola is often cited by papers focused on Immunotherapy and Immune Responses (20 papers), CAR-T cell therapy research (17 papers) and Virus-based gene therapy research (14 papers). Sara Feola collaborates with scholars based in Finland, Italy and Netherlands. Sara Feola's co-authors include Vincenzo Cerullo, Erkko Ylösmäki, Jacopo Chiaro, Beatriz Martins, Manlio Fusciello, Cristian Capasso, Karita Peltonen, Salvatore Russo, Firas Hamdan and Siri Tähtinen and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Sara Feola

32 papers receiving 678 citations

Peers

Sara Feola

ONCOL

IMMUN

GENET

Manlio Fusciello Finland

Beatriz Martins Finland

Cristian Capasso Finland

Nicolas Boisgerault France

Joost H. van den Berg Netherlands

Firas Hamdan Finland

Megha Shettigar United States

Lora K. Picton United States

Coralie M. Backlund United States

Lien Vandenberk Belgium

Manlio Fusciello Finland

Sara Feola

263 ×0.8

264 ×0.8

ONCOL

236 ×0.8

IMMUN

183 ×0.8

GENET

115 ×1.0

Citations per year, relative to Sara Feola Sara Feola (= 1×) peers Manlio Fusciello

Countries citing papers authored by Sara Feola

Since Specialization

Citations

This map shows the geographic impact of Sara Feola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Feola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Feola more than expected).

Fields of papers citing papers by Sara Feola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Feola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Feola. The network helps show where Sara Feola may publish in the future.

Co-authorship network of co-authors of Sara Feola

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Feola. A scholar is included among the top collaborators of Sara Feola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Feola. Sara Feola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chiaro, Jacopo, Karita Peltonen, Kadri Õunap, et al.. (2025). Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates. npj Vaccines. 10(1). 195–195. 1 indexed citations

Feola, Sara, Firas Hamdan, Salvatore Russo, et al.. (2024). Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors. Journal for ImmunoTherapy of Cancer. 12(3). e008342–e008342. 7 indexed citations

Falanga, Andrea Patrizia, Monica Terracciano, Stefano D’Errico, et al.. (2024). Engineering an oncolytic adenoviral platform for precise delivery of antisense peptide nucleic acid to modulate PD-L1 overexpression in cancer cells. International Journal of Pharmaceutics. 668. 124941–124941. 2 indexed citations

Feola, Sara, Ilaria Granata, Thomas Whalley, et al.. (2023). Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma. iScience. 26(10). 107668–107668. 17 indexed citations

Feola, Sara, Jacopo Chiaro, & Vincenzo Cerullo. (2023). Integrating immunopeptidome analysis for the design and development of cancer vaccines. Seminars in Immunology. 67. 101750–101750. 14 indexed citations

Hamdan, Firas, Salvatore Russo, Manlio Fusciello, et al.. (2023). Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses. Molecular Therapy — Oncolytics. 28. 264–276. 2 indexed citations

Feola, Sara, Marco Pirazzini, Stefano Salmaso, et al.. (2022). Mannosylated Polycations Target CD206⁺ Antigen-Presenting Cells and Mediate T-Cell-Specific Activation in Cancer Vaccination. Biomacromolecules. 23(12). 5148–5163. 10 indexed citations

Fusciello, Manlio, Erkko Ylösmäki, Sara Feola, et al.. (2022). A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella. Molecular Therapy — Oncolytics. 25. 137–145. 3 indexed citations

Feola, Sara, Salvatore Russo, Beatriz Martins, et al.. (2022). Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. Frontiers in Immunology. 13. 826164–826164. 14 indexed citations

10.

Feola, Sara, Jacopo Chiaro, Beatriz Martins, et al.. (2022). A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. eLife. 11. 26 indexed citations

11.

Xu, Wujun, Chaojun Song, Jing Xia Qian, et al.. (2022). Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy. Acta Biomaterialia. 152. 473–483. 14 indexed citations

12.

Ylösmäki, Erkko, Manlio Fusciello, Beatriz Martins, et al.. (2021). Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin. Journal for ImmunoTherapy of Cancer. 9(7). e002707–e002707. 22 indexed citations

13.

Peltonen, Karita, Sara Feola, Husen M. Umer, et al.. (2021). Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy. Cancers. 13(14). 3408–3408. 17 indexed citations

14.

Chiaro, Jacopo, Thomas Whalley, Cristian Capasso, et al.. (2021). Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. Cancer Immunology Research. 9(8). 981–993. 25 indexed citations

15.

Tähtinen, Siri, Sara Feola, Cristian Capasso, et al.. (2020). Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Cancer Research. 80(12). 2575–2585. 40 indexed citations

16.

Fontana, Flavia, Manlio Fusciello, Christianne Groeneveldt, et al.. (2019). Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. ACS Nano. 13(6). 6477–6490. 40 indexed citations

17.

Fusciello, Manlio, Flavia Fontana, Siri Tähtinen, et al.. (2019). Artificially cloaked viral nanovaccine for cancer immunotherapy. Nature Communications. 10(1). 5747–5747. 97 indexed citations

18.

Polini, Beatrice, Sara Carpi, Beatriz Martins, et al.. (2019). Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy. PLoS ONE. 14(10). e0224072–e0224072. 7 indexed citations

19.

Lopes, Alessandra, Sara Feola, Manlio Fusciello, et al.. (2019). Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. Journal for ImmunoTherapy of Cancer. 7(1). 174–174. 17 indexed citations

20.

Feola, Sara, Cristian Capasso, Manlio Fusciello, et al.. (2018). Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. OncoImmunology. 7(8). e1457596–e1457596. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact